Physician profile
Ihab Beblawi
NPI 1942272075
$6,735.81
in general payments reported to CMS, 2019-2025
29 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $285 · 2021: $1,000 · 2022: $1,206 · 2023: $1,026 · 2024: $1,051 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,414.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,666.88 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $424.86 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $389.09 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $262.36 | 2020-2025 | Stelara, Tremfya |
| Celltrion USA INC. | $211.83 | 2024-2025 | Zymfentra, Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.00 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $160.04 | 2025 | General - Therapies, General - Biliary Devices |
| Apollo Endosurgery US INC | $139.18 | 2023 | Overstitch Endoscopic Suturing System |
| Pfizer INC. | $130.62 | 2019-2023 | |
| Qol Medical, LLC | $127.95 | 2019-2023 | Sucraid |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Lilly USA, LLC | $106.29 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $98.35 | 2021-2024 | Dificid |
| Aimmune Therapeutics, INC. | $89.00 | 2024 | |
| Mauna Kea Technologies, INC. | $87.93 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $80.40 | 2019 | |
| Erbe USA INC | $74.21 | 2019 | |
| Covidien LP | $64.94 | 2019 | |
| Intercept Pharmaceuticals, INC. | $46.11 | 2020-2023 | Ocaliva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2024 | Cyltezo |
| Redhill Biopharma INC. | $32.39 | 2021 | |
| Gilead Sciences, INC. | $30.40 | 2019 | |
| Shionogi INC | $27.65 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $25.42 | 2024 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $25.00 | 2021 | |
| Allergan, INC. | $19.55 | 2019 | |
| Lucid Diagnostics INC. | $16.75 | 2022 | |
| Celgene Corporation | $16.70 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $15.32 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ihab Beblawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.